mmitteeAnalyses of both trials indi

mmittee
Analyses of both trials indicate that observed reduction in prostate cancer risk on taking finasteride and dutasteride was limited to tumors that had mGS of ≤ 6.
Data collected in REDUCE trial indicates that 80% of these cancers belong to ‘very low risk’ category (Epstein pathological criteria) and hence, their clinical significance is negligible.
Use of 5 α reductase inhibitor drugs may hence prevent 3 to 4 low-grade cancers at the expense of one high-grade prostate cancer.
The committee concluded that both drugs do not have significant risk-benefit profile for preventing prostate cancer in healthy men.

Результаты (английский) 1:

mmitteeAnalyses of both trials indicate that the observed reduction in prostate cancer risk on taking finasteride and dutasteride was limited to tumors that had mGS of ≤ 6.Data collected in the REDUCE trial indicates that 80% of these cancers belong to very low ' risk ' category (Epstein pathological criteria) and hence, their clinical significance is negligible.Use of 5 α reductase an drugs may hence prevent 3 to 4 low grade cancers at the expense of one high grade prostate cancer.The committee concluded that both drugs do not have significant risk-benefit profile for preventing prostate cancer in healthy men.

Результаты (английский) 2:

mmittee
the Analyses of Both trials Indicate That Observed reduction clause in prostate cancer risk on taking of finasteride and dutasteride WAS Limited to Tumors That HAD Mgs of ≤ 6.
the Data Collected in the REDUCE by trial Indicates the That 80% of these cancers belong to 'very low risk' category ( Epstein Pathological Criteria) and hence, Their clinical Significance is negligible.
the Use of 5 α reductase inhibitor drugs may hence prevent 3 to 4 of low-grade cancers AT the Expense of one's the high-grade prostate cancer.
of the Committee Concluded That Both drugs do not have significant risk-benefit profile for preventing prostate cancer in healthy men.